Portal de Periódicos da CAPES

Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences

2010; Elsevier BV; Volume: 37; Issue: 7 Linguagem: Inglês

10.1016/j.nucmedbio.2010.04.185

1872-9614

Heinz H. Coenen, Philip H. Elsinga, Ren Iwata, Michael R. Kilbourn, M.R.A. Pillai, M. G. R. Rajan, H. N. Wagner, John J. Zaknun,

Neuroendocrine Tumor Research Advances

Positron emission tomography (PET) is a rapidly expanding clinical modality worldwide thanks to the availability of compact medical cyclotrons and automated chemistry for the production of radiopharmaceuticals. There is an armamentarium of fluorine-18 (18F) tracers that can be used for PET studies in the fields of oncology and neurosciences. However, most of the 18F-tracers other than 2-deoxy-2-[18F]fluoro-D-glucose (FDG) are in less than optimum human use and there is considerable scope to bring potentially useful 18F-tracers to clinical investigation stage. The International Atomic Energy Agency (IAEA) convened a consultants' group meeting to review the current status of 18F-based radiotracers and to suggest means for accelerating their use for diagnostic applications. The consultants reviewed the developments including the synthetic approaches for the preparation of 18F-tracers for oncology and neurosciences. A selection of three groups of 18F-tracers that are useful either in oncology or in neurosciences was done based on well-defined criteria such as application, lack of toxicity, availability of precursors and ease of synthesis. Based on the recommendations of the consultants' group meeting, IAEA started a coordinated research project on "Development of 18F radiopharmaceuticals (beyond [18F]FDG) for use in oncology and neurosciences" in which 14 countries are participating in a 3-year collaborative program. The outcomes of the coordinated research project are expected to catalyze the wider application of several more 18F-radiopharmaceuticals beyond FDG for diagnostic applications in oncology and neurosciences.